

Clerk of the House of Representatives  
Legislative Resource Center  
B-106 Cannon Building  
Washington, DC 20515

Secretary of the Senate  
Office of Public Records  
232 Hart Building  
Washington, DC 20510

SECRETARY OF T

03 FEB 28 A

# LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name <b>Watson Pharmaceuticals, Inc. (New Jersey)</b>			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address <b>1101 17th Street N.W.</b> Suite <b>500</b> City <b>Washington</b> State/Zip (or Country) <b>DC 20036</b>			
3. Principal Place of Business (if different from line 2) City <b>Corona</b> State/Zip (or Country) <b>CA 92880</b>			
4. Contact Name <b>G. Thomas Long</b>	Telephone <b>202-452-1102</b>	E-mail (optional) <b>gtlong@earthlink.net</b>	5. Senate ID # <b>63837-12</b>
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID # <b>35518000</b>

**TYPE OF REPORT** 8. Year 2002 Midyear (January 1-June 30) ☒ **OR** Year End (July 1-Dec 31) ☐

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ >> Termination Date 12/1/02 11. No Lobbying ☐

## INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
<b>INCOME</b> relating to lobbying activities for this reporting period was: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input type="checkbox"/> >> \$ _____ <div style="text-align: right;">Income (nearest \$20,000)</div>	<b>EXPENSES</b> relating to lobbying activities for this reporting period were: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$200,000.00</u> <div style="text-align: right;">Expenses (nearest \$20,000)</div>
<b>14. REPORTING METHOD.</b> Check box to indicate accounting method. See instructions for description of methods.	
<input checked="" type="checkbox"/> <b>Method A.</b> Reporting amounts using LDA definition	
<input type="checkbox"/> <b>Method B.</b> Reporting amounts under section 6011 of the Internal Revenue Code	
<input type="checkbox"/> <b>Method C.</b> Reporting amounts under section 162 of the Internal Revenue Code	

Signature \_\_\_\_\_ Date 02/14/2003

Printed Name and Title G. Thomas Long - Vice President, Government Affairs P.



Registrant Name: Watson Pharmaceuticals, Inc. (New Jersey)

Client Name: Watson Pharmaceuticals, Inc. (New Jersey)

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific Lobbying issues

**HR 5263 S 2801, FY 2003 Agriculture Appropriations Bill, FDA Appropriations: OGD**

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

**House of Representatives**

**Senate**

LobbyRiot

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Long, G. Thomas	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature \_\_\_\_\_ Date 02/14/2003

Printed Name and Title **G. Thomas Long - Vice President, Government Affairs** P:

Registrant Name: Watson Pharmaceuticals, Inc. (New Jersey)

Client Name: Watson Pharmaceuticals, Inc. (New Jersey)

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific Lobbying issues

**HR 1862, Greater Access to Affordable Pharmaceuticals Act,**

**HR 5311, Prescription Drug Affordability Act,**

**S 2677, Consumer Access to Prescription Drugs Improvement Act of 2002,**

**S 812, Greater Access for Affordable Pharmaceuticals Act,**

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

**House of Representatives**

**Senate**

**White House**

Lobby Rpt.

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Long, G. Thomas	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature \_\_\_\_\_ Date 02/14/2003

Printed Name and Title **G. Thomas Long - Vice President, Government Affairs** Pa

Registrant Name: Watson Pharmaceuticals, Inc. (New Jersey)

Client Name: Watson Pharmaceuticals, Inc. (New Jersey)

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific Lobbying issues

**HR 3448, Public Health Security and Bioterrorism Response Act of 2001,  
Letters and visits to Members of Congress and Federal officials regarding Food and Drug Administration r  
activity covering issues and products of interest to the Registrant.**

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

**Food & Drug Administration  
House of Representatives  
Senate**

LobbyRpt.

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Long, G. Thomas	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature \_\_\_\_\_ Date 02/19/2003

Printed Name and Title G. Thomas Long - Vice President, Government Affairs Page



Registrant Name: Watson Pharmaceuticals, Inc. (New Jersey)

Client Name: Watson Pharmaceuticals, Inc. (New Jersey)

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code LBR (one per page)

16. Specific Lobbying issues  
S 754, Drug Competition Act of 2001,

17. House(s) of Congress and Federal agencies contacted  
House of Representatives  
Senate

☐ Check if None

LobbyRpt.

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Long, G. Thomas	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature \_\_\_\_\_ Date 02/14/2003

Printed Name and Title G. Thomas Long - Vice President, Government Affairs Page

Registrant Name: Watson Pharmaceuticals, Inc. (New Jersey)

Client Name: Watson Pharmaceuticals, Inc. (New Jersey)

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)
16. Specific Lobbying issues  
**HR 4954, Medicare Modernization & Prescription Drug Act of 2002,**  
**S 1135, Medicare Reform Act of 2001,**  
**S 2625, Medicare Outpatient Prescription Drug Act of 2002,**

17. House(s) of Congress and Federal agencies contacted  
**House of Representatives**  
**Senate**  
**White House**


☐ Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Long, G. Thomas	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature  Date 02/14/2003  
Printed Name and Title G. Thomas Long - Vice President, Government Affairs Page